Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
The conversation discusses optimizing sulforaphane in broccoli sprouts by soaking them in water at 74 degrees Celsius for 10 minutes. It also mentions hair loss treatments like Minoxidil, finasteride, and RU58841.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.
Bryan Johnson used a customized hair restoration formula from Roots byGA, which includes Minoxidil, Cetirizine HCl, Latanoprost, Dutasteride, Melatonin, Caffeine, Tretinoin, Vitamin D3, and Vitamin E. Many users are skeptical of the effectiveness and uniqueness of the treatment, suggesting that standard treatments like Minoxidil and Dutasteride are more reliable.
The user seeks alternatives to Propylene Glycol (PG) for delivering topical finasteride due to scalp irritation. They consider using Propanediol 1,3 and ask for other suggestions.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.
The conversation discusses the effectiveness of Regenera Activia stem cells versus Cellgenic exosomes for hair loss treatment. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without results.
The conversation discusses hair loss treatments, specifically seeking a 15% glycyrrhizic acid formula without additional ingredients. It also mentions the potential opposite effects of glycyrrhizic acid on humans compared to rats.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
The conversation discusses hair loss treatments, specifically Brassica oleracea extract, glucosinolates, and sulforaphane, and their potential to promote hair growth. Users also mention minoxidil and finasteride as existing treatments.
A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.
The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.
A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
Crushing spironolactone pills and combining them with minoxidil for topical application may be effective for hair loss, with the addition of finasteride suggested. Adding rosemary and peppermint oils can help mask the unpleasant smell.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.